GeneEdit Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $500M
Overview
A gene editing biotech creating potentially curative therapies for genetic diseases using precision CRISPR-based technologies.
Genetics & GenomicsRare DiseasesOphthalmology
Technology Platform
Develops proprietary CRISPR-based gene editing systems and delivery methods to safely and precisely correct disease-causing mutations.
Funding History
1Total raised:$500M
IPO$500M
Opportunities
Potential to address a vast array of genetic disorders with a single, durable therapeutic platform.
Risk Factors
Faces significant scientific risks related to off-target effects, immune responses, and long-term safety of gene editing in humans.
Competitive Landscape
Enters a crowded but high-potential field, competing with established gene editing leaders on the specificity and delivery of its technology.